Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1 as potentially having an oncogenic role in breast cancer.
Rebecca Feldman, PhD, molecular science liaison/research scientist, Caris Life Sciences, discusses caveolin-1, which could potentially have an oncogenic role in breast cancer.
In a recent study, researchers sought to determine whether caveolin-1 (CAV1) is a tumor suppressor or a proto-oncogene in patients with breast cancer. Due to known interactions with signaling molecules, it was investigated whether or not CAV1-positive breast cancers differ from CAV1-negative breast cancers.
CAV1 positivity was found to be significantly associated with triple-negative breast cancer (TNBC) status, which coincided with earlier studies. A further analysis examined patients with CAV1-positive TNBC versus CAV1-negative TNBC. EGFR was found to be upregulated in patients with CAV1-positivity by protein expression. Additionally, overexpression of PDGFRA, ERCC1, and TLE3 were also found in CAV1-positive patients.